965 related articles for article (PubMed ID: 9300034)
1. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
2. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain.
Deml L; Kratochwil G; Osterrieder N; Knüchel R; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):10-25. PubMed ID: 9300033
[TBL] [Abstract][Full Text] [Related]
3. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
4. Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles.
Wagner R; Deml L; Schirmbeck R; Niedrig M; Reimann J; Wolf H
Virology; 1996 Jun; 220(1):128-40. PubMed ID: 8659105
[TBL] [Abstract][Full Text] [Related]
5. Induction of V3-specific cytotoxic T lymphocyte responses by HIV gag particles carrying multiple immunodominant V3 epitopes of gp120.
Luo L; Li Y; Chang JS; Cho SY; Kim TY; Choi MJ; Cheong HS; Kim HJ; Ahn HJ; Min MK; Chun BH; Jung SM; Woo SG; Park SY; Kang CY
Virology; 1998 Jan; 240(2):316-25. PubMed ID: 9454705
[TBL] [Abstract][Full Text] [Related]
6. Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles.
Wagner R; Deml L; Fliessbach H; Wanner G; Wolf H
Virology; 1994 Apr; 200(1):162-75. PubMed ID: 7510434
[TBL] [Abstract][Full Text] [Related]
7. Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit Gag- and SU-specific murine cytotoxic T-lymphocyte activities.
Tobin GJ; Li GH; Fong SE; Nagashima K; Gonda MA
Virology; 1997 Sep; 236(2):307-15. PubMed ID: 9325238
[TBL] [Abstract][Full Text] [Related]
8. Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development.
Wagner R; Deml L; Schirmbeck R; Reimann J; Wolf H
Behring Inst Mitt; 1994 Dec; (95):23-34. PubMed ID: 7755506
[TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model.
Notka F; Stahl-Hennig C; Dittmer U; Wolf H; Wagner R
Biol Chem; 1999 Mar; 380(3):341-52. PubMed ID: 10223337
[TBL] [Abstract][Full Text] [Related]
10. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
11. Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans.
Doe B; Steimer KS; Walker CM
Eur J Immunol; 1994 Oct; 24(10):2369-76. PubMed ID: 7523139
[TBL] [Abstract][Full Text] [Related]
12. Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model.
Wild J; Bojak A; Deml L; Wagner R
Vaccine; 2004 Apr; 22(13-14):1732-43. PubMed ID: 15068857
[TBL] [Abstract][Full Text] [Related]
13. Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses.
Wagner R; Böltz T; Deml L; Modrow S; Wolf H
J Gen Virol; 1993 Jul; 74 ( Pt 7)():1261-9. PubMed ID: 7687647
[TBL] [Abstract][Full Text] [Related]
14. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
AIDS Vaccine Evaluation Group 022 Protocol Team
J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
[TBL] [Abstract][Full Text] [Related]
15. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT; Boo I; Drummer HE; Netter HJ
Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T cell repertoire selection. A single amino acid determines alternative class I restriction.
Bergmann CC; Tong L; Cua RV; Sensintaffar JL; Stohlman SA
J Immunol; 1994 Jun; 152(12):5603-12. PubMed ID: 7515908
[TBL] [Abstract][Full Text] [Related]
17. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
Akerblom L; Nara P; Dunlop N; Putney S; Morein B
Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
[TBL] [Abstract][Full Text] [Related]
18. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
McBurney SP; Young KR; Ross TM
Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
[TBL] [Abstract][Full Text] [Related]
19. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein.
Bergmann C; Stohlmann SA; McMillan M
Eur J Immunol; 1993 Nov; 23(11):2777-81. PubMed ID: 7693478
[TBL] [Abstract][Full Text] [Related]
20. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.
Stanhope PE; Liu AY; Pavlat W; Pitha PM; Clements ML; Siliciano RF
J Immunol; 1993 May; 150(10):4672-86. PubMed ID: 8097759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
